US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DAMORA THERAPEUT

20.67

-0.6150-2.89%

Volume:44.17K

Turnover:918.02K

Market Cap:1.27B

PE:-2.09

High:21.25

Open:20.51

Low:20.48

Close:21.28

52wk High:38.33

52wk Low:3.50

Shares:61.55M

Float Shares:47.65M

Volume Ratio:0.36

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-9.8764

EPS(LYR):-153.9532

ROE:-99.74%

ROA:-21.61%

PB:3.29

PE(LYR):-0.13

Loading ...

Overview Company News Filings

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Damora Therapeutics Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $35

THOMSON REUTERS

Damora Therapeutics (DMRA) Receives a Rating Update from a Top Analyst

U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology

Damora Therapeutics Inc : Leerink Partners Cuts Target Price to $51 From $55

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA) and vTv Therapeutics (VTVT)

RBC Capital Remains a Buy on Damora Therapeutics (DMRA)

BRIEF-Damora Therapeutics Reports First Quarter 2026 Financial Results

Damora Therapeutics posts corporate deck on mutCALR-targeted therapies for MPN blood cancers

Damora Therapeutics: Q1 EPS $-0.62

THOMSON REUTERS

Damora Therapeutics Inc - on Track for First Regulatory Submission for Dmr-001 in Mid-2026

THOMSON REUTERS

Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Damora net loss widens to $27.78 million in Q1 2026

Damora Therapeutics SVP Finance Brian Burkavage files initial beneficial ownership statement

A Look At Damora Therapeutics (DMRA) Valuation After Recent Share Price Momentum And Negative Equity Signals

Simply Wall St.

BRIEF-Damora Therapeutics: Lori Firmani To Cease Serving As CFO Effective May 1, 2026 - SEC Filing

Damora Therapeutics Inc - Lori Firmani to Cease Serving as CFO Effective May 1, 2026 - SEC Filing

THOMSON REUTERS

Damora Therapeutics names Brian Burkavage principal financial officer, accounting officer

Damora Therapeutics grants options for 57,500 shares at $25.66 under inducement plan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/DMRA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DMRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMRA\",,,,,undefined,":{"symbol":"DMRA","market":"US","secType":"STK","nameCN":"DAMORA THERAPEUT","latestPrice":20.665,"timestamp":1790865205108,"preClose":21.28,"halted":0,"volume":44172,"delay":0,"changeRate":-0.028900375939849714,"floatShares":47648701,"shares":61553200,"eps":-9.876431,"marketStatus":"Trading","change":-0.615,"latestTime":"10-01 10:33:51 EDT","open":20.512,"high":21.25,"low":20.48,"amount":918022.2588000001,"amplitude":0.036184,"askPrice":20.8,"askSize":100,"bidPrice":20.49,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-9.876431,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790884800000},"marketStatusCode":2,"adr":0,"listingDate":1603944000000,"exchange":"NASDAQ","adjPreClose":21.28,"preHourTrading":{"tag":"盘前","latestPrice":21.28,"preClose":21.28,"latestTime":"08:19 EDT","volume":146,"amount":3106.6902,"timestamp":1790857186111,"change":0,"changeRate":0,"amplitude":0.020207},"postHourTrading":{"tag":"盘后","latestPrice":21.28,"preClose":21.28,"latestTime":"19:30 EDT","volume":10335,"amount":219926.97,"timestamp":1790811003527,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.357813},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DMRA\",,,,,undefined,":{"symbol":"DMRA","floatShares":47648701,"roa":"-21.61%","roe":"-99.74%","lyrEps":-153.953213,"volumeRatio":0.357813,"shares":61553200,"dividePrice":0,"high":21.25,"amplitude":0.036184,"preClose":21.28,"low":20.48,"week52Low":3.5,"pbRate":"3.29","week52High":38.3251,"institutionHeld":0,"latestPrice":20.665,"eps":-9.876431,"divideRate":0,"volume":44172,"delay":0,"ttmEps":-9.876431,"open":20.512,"prevYearClose":23.01,"prevWeekClose":20.66,"prevMonthClose":21.28,"prevQuarterClose":21.28,"fiveDayClose":20.27,"twentyDayClose":28.18,"sixtyDayClose":27.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DMRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-12","symbol":"DMRA","fiscalQuarterEnding":"2026/03","expectedEps":-0.21,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"post","actualEps":-0.62},{"market":"US","date":"2026-03-19","symbol":"DMRA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773892800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-06","symbol":"DMRA","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-2.36},{"market":"US","date":"2025-08-05","symbol":"DMRA","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-2.6},{"market":"US","date":"2025-05-08","symbol":"DMRA","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-1.92}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DMRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DMRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":10,"updateTime":1785124800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DMRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DMRA","date":"2026-09-30","current":-2.092355,"percent":0.978417,"low":-100.260711,"twenty":-7.672431,"median":-7.116085,"eighty":-6.102207,"high":-4.761245,"avg":-11.695617,"sd":19.959486,"marketCap":1275455822},"quantilePoints":[{"date":"2026-03-13","current":-100.260711,"twenty":-100.260711,"median":-100.260711,"eighty":-98.29884,"marketCap":1588530698},{"date":"2026-03-20","current":-72.999835,"twenty":-100.199878,"median":-95.983376,"eighty":-84.763454,"marketCap":1156609382},{"date":"2026-03-27","current":-7.36551,"twenty":-98.861547,"median":-80.41388,"eighty":-7.003988,"marketCap":1545571323},{"date":"2026-04-02","current":-7.207452,"twenty":-96.587906,"median":-7.443103,"eighty":-7.019507,"marketCap":1512404556},{"date":"2026-04-10","current":-7.670132,"twenty":-94.238224,"median":-7.361199,"eighty":-7.021806,"marketCap":1609492728},{"date":"2026-04-17","current":-7.759219,"twenty":-89.113027,"median":-7.443103,"eighty":-7.088477,"marketCap":1628186724},{"date":"2026-04-24","current":-7.305161,"twenty":-78.931071,"median":-7.519258,"eighty":-7.200555,"marketCap":1532907649},{"date":"2026-05-01","current":-7.374132,"twenty":-59.951712,"median":-7.420112,"eighty":-7.071235,"marketCap":1547380419},{"date":"2026-05-08","current":-7.181588,"twenty":-7.748873,"median":-7.369821,"eighty":-7.098823,"marketCap":1506977267},{"date":"2026-05-15","current":-6.125513,"twenty":-7.702318,"median":-7.328151,"eighty":-6.979849,"marketCap":1440040702},{"date":"2026-05-22","current":-6.376895,"twenty":-7.679328,"median":-7.296539,"eighty":-6.874668,"marketCap":1499137850},{"date":"2026-05-29","current":-6.50384,"twenty":-7.670132,"median":-7.208889,"eighty":-6.624282,"marketCap":1528981338},{"date":"2026-06-05","current":-5.841412,"twenty":-7.647141,"median":-7.181588,"eighty":-6.506459,"marketCap":1373251758},{"date":"2026-06-12","current":-5.592674,"twenty":-7.644267,"median":-7.103996,"eighty":-6.310202,"marketCap":1314776223},{"date":"2026-06-18","current":-5.608384,"twenty":-7.605184,"median":-7.036462,"eighty":-6.158347,"marketCap":1318469415},{"date":"2026-06-26","current":-5.909488,"twenty":-7.595413,"median":-6.974676,"eighty":-5.98699,"marketCap":1389255588},{"date":"2026-07-02","current":-7.092956,"twenty":-7.5092,"median":-6.96318,"eighty":-6.007936,"marketCap":1667476025},{"date":"2026-07-10","current":-8.059107,"twenty":-7.645417,"median":-7.006288,"eighty":-6.078901,"marketCap":1894607311},{"date":"2026-07-17","current":-7.917719,"twenty":-7.67473,"median":-7.092956,"eighty":-6.150138,"marketCap":1861368586},{"date":"2026-07-24","current":-7.637561,"twenty":-7.776537,"median":-7.12986,"eighty":-6.183485,"marketCap":1795506668},{"date":"2026-07-31","current":-7.648035,"twenty":-7.738833,"median":-7.190209,"eighty":-6.195797,"marketCap":1797968796},{"date":"2026-08-07","current":-7.82346,"twenty":-7.815082,"median":-7.208161,"eighty":-6.219919,"marketCap":1839209436},{"date":"2026-08-14","current":-7.218207,"twenty":-7.815082,"median":-7.209243,"eighty":-6.276357,"marketCap":1897132498},{"date":"2026-08-21","current":-7.119553,"twenty":-7.785196,"median":-7.218207,"eighty":-6.321676,"marketCap":1871203580},{"date":"2026-08-28","current":-7.187671,"twenty":-7.738833,"median":-7.209243,"eighty":-6.354091,"marketCap":1889106881},{"date":"2026-09-04","current":-6.576954,"twenty":-7.707949,"median":-7.198831,"eighty":-6.380999,"marketCap":1728594532},{"date":"2026-09-11","current":-6.30448,"twenty":-7.706597,"median":-7.187671,"eighty":-6.346489,"marketCap":1656981329},{"date":"2026-09-18","current":-5.350822,"twenty":-7.698741,"median":-7.142724,"eighty":-6.305624,"marketCap":1406335122},{"date":"2026-09-25","current":-4.761245,"twenty":-7.679328,"median":-7.119553,"eighty":-6.175428,"marketCap":1251378970},{"date":"2026-09-30","current":-4.852853,"twenty":-7.672431,"median":-7.116085,"eighty":-6.102207,"marketCap":1275455822}],"updateTime":1790865231963},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DMRA\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640095917","title":"Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640095917","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640095917?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315205,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUACGPDTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640006959","title":"Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640006959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640006959?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315200,"startTime":"0","endTime":"0","summary":"BOSTON, June  01, 2026  (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304320/0/en/Damora-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","LENZ","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638666780","title":"Damora Therapeutics Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2638666780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638666780?lang=en_us&edition=fundamental","pubTime":"2026-05-28 18:52","pubTimestamp":1779965532,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nFWN4250AY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636018490","title":"Damora Therapeutics (DMRA) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2636018490","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636018490?lang=en_us&edition=fundamental","pubTime":"2026-05-18 00:48","pubTimestamp":1779036480,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Damora Therapeutics yesterday and set a price target of $45.00. Slutsky covers the H...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/damora-therapeutics-dmra-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/damora-therapeutics-dmra-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635358799","title":"U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2635358799","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635358799?lang=en_us&edition=fundamental","pubTime":"2026-05-14 15:24","pubTimestamp":1778743446,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology May 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cisc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL4N41R0NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CIFU","DT","BXP","CORZ","AVB","DOCS","ABBV","AEE","CLH","ASTH","MVLL","ET","ARMK","CMP","CGON","CAVA","CVNX","CAKE","CSR","CSCL","CVNY","ANDG","ASO","CMC","DECK","MRVL","DMRA","AVTX","CSCO","AMGN","ARVN","AFRU","DLLL","CSCS","CVNA","AFRM","DELL","AN","CIFG","CIFR","ATLC","DTE","MRVU","AKAM","APGE","CPT","CMS","EBAY","ANTX","CARR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635769831","title":"Damora Therapeutics Inc : Leerink Partners Cuts Target Price to $51 From $55","url":"https://stock-news.laohu8.com/highlight/detail?id=2635769831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635769831?lang=en_us&edition=fundamental","pubTime":"2026-05-14 11:24","pubTimestamp":1778729084,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nFWN41Q19H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635750222","title":"Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA) and vTv Therapeutics (VTVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635750222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635750222?lang=en_us&edition=fundamental","pubTime":"2026-05-14 09:00","pubTimestamp":1778720410,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Damora Therapeutics (DMRA) and vTv Therapeutics (VTV...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-damora-therapeutics-dmra-and-vtv-therapeutics-vtvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-damora-therapeutics-dmra-and-vtv-therapeutics-vtvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4585","BK4588","VTVT","BK4137","LABU","LU0128526141.USD","LU0029874061.USD","BK4139","XBI","XLV","HCSG","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635781639","title":"RBC Capital Remains a Buy on Damora Therapeutics (DMRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635781639","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635781639?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:38","pubTimestamp":1778672322,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Damora Therapeutics, with a price target of $40.00. The ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-damora-therapeutics-dmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-damora-therapeutics-dmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU0029864427.USD","DMRA","LU0128525929.USD","LU0310800379.SGD","BK4207","BK4139","LU1267930573.SGD","LENZ","LU0708994859.HKD","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635256302","title":"BRIEF-Damora Therapeutics Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635256302","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635256302?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:43","pubTimestamp":1778622212,"startTime":"0","endTime":"0","summary":"BRIEF-Damora Therapeutics Reports First Quarter 2026 Financial Results May 12 (Reuters) - Damora Therapeutics Inc DMRA.O:DAMORA THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT COR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA7M5BJF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240961","title":"Damora Therapeutics posts corporate deck on mutCALR-targeted therapies for MPN blood cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240961","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240961?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:21","pubTimestamp":1778617298,"startTime":"0","endTime":"0","summary":"Damora outlined development plans for mutCALR-targeted antibody programs in myeloproliferative neoplasms, highlighting lead asset DMR-001 with first regulatory submission targeted for mid-2026.DMR-001 described as Fc-null, extended half-life antibody designed to block mutCALR-driven signaling without immune effector engagement, with subcutaneous dosing planned at every 4 weeks or longer using an autoinjector.Pipeline timeline also showed DMR-002, an Fc-enhanced anti-mutCALR antibody with first regulatory submission expected in 2H 2026, alongside DMR-003, a mutCALR x CD3 T-cell engager with first regulatory submission expected in 2027.Presentation cited about $533 million in cash to advance DMR-001 through proof-of-concept into registrational development.Market sizing in mutCALR-driven essential thrombocythemia and myelofibrosis estimated at more than $5 billion in total addressable market in US, with about 42,000 prevalent mutCALR-driven MPN patients.Disclaimer: This news brief was cre","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL21rXFD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635225562","title":"Damora Therapeutics: Q1 EPS $-0.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2635225562","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635225562?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616304,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA7M5BJF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635225537","title":"Damora Therapeutics Inc - on Track for First Regulatory Submission for Dmr-001 in Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635225537","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635225537?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA7M5BJF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635424063","title":"Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635424063","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635424063?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"– DMR-001 preclinical data showcasing potentially best-in-class potency, half-life and anti-mutCALR activity to be presented at 2026 European Hematology Association Congress – – On track to submit fir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293403/0/en/Damora-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Recent-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4106","BK4590","BK4588","ET","BK4561","BK4007","BK4226","BK4581","LENZ","XELA","BK4585","BK4144","DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635724203","title":"Damora net loss widens to $27.78 million in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635724203","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635724203?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:03","pubTimestamp":1778616184,"startTime":"0","endTime":"0","summary":"Damora Therapeutics posted a net loss of $27.78 million, swinging from a net loss of $2.53 million a year earlier.Operating loss widened to $30.81 million from $2.6 million, as total operating expenses climbed to $30.81 million from $2.6 million.Research and development costs jumped to $23.78 million from $678,000, including $17 million tied to services provided by Paragon under the Paragon Option Agreement.General and administrative expense rose to $7.03 million from $1.92 million, while other income increased to $3.07 million from $68,000 on higher interest income following recent financings.Cash and cash equivalents totaled $532.9 million as of March 31, 2026; Damora said it expects existing cash to fund operations into 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLbJKP6M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634467373","title":"Damora Therapeutics SVP Finance Brian Burkavage files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2634467373","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634467373?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:01","pubTimestamp":1778274065,"startTime":"0","endTime":"0","summary":"Damora Therapeutics SVP, Finance Brian Burkavage reported a stock option covering 312,535 common shares at USD 32, expiring Dec. 15, 2035.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDLb8RNMf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633291900","title":"A Look At Damora Therapeutics (DMRA) Valuation After Recent Share Price Momentum And Negative Equity Signals","url":"https://stock-news.laohu8.com/highlight/detail?id=2633291900","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633291900?lang=en_us&edition=fundamental","pubTime":"2026-05-05 18:20","pubTimestamp":1777976448,"startTime":"0","endTime":"0","summary":"Damora Therapeutics stock snapshot\nDamora Therapeutics (DMRA) has drawn investor attention after recent share price moves, with the stock closing at US$25.93 and showing mixed return patterns across the past week, month, past 3 months and year to date.\nSee our latest analysis for Damora Therapeutics.\nThe recent 1-day and 30-day share price returns of 2.25% and 3.35% respectively come on top of an 18.84% year to date share price return. The 1-year total shareholder return is around 7.5x, set...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmra/damora-therapeutics/news/a-look-at-damora-therapeutics-dmra-valuation-after-recent-sh","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dmra/damora-therapeutics/news/a-look-at-damora-therapeutics-dmra-valuation-after-recent-sh","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4539","BK4139","EQR","DMRA","LENZ","BK4588","BK4215","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633966202","title":"BRIEF-Damora Therapeutics: Lori Firmani To Cease Serving As CFO Effective May 1, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2633966202","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633966202?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:31","pubTimestamp":1777926696,"startTime":"0","endTime":"0","summary":"BRIEF-Damora Therapeutics: Lori Firmani To Cease Serving As CFO Effective May 1, 2026 - SEC FilingMay 4  - Damora Therapeutics Inc DMRA.O:DAMORA THERAPEUTICS INC - LORI FIRMANI TO CEASE SERVING AS CFO EFFECTIVE MAY 1, 2026 - SEC FILINGDAMORA THERAPEUTICS INC - APPOINTS BRIAN BURKAVAGE AS PRINCIPAL FINANCIAL OFFICER EFFECTIVE MAY 1, 2026 - SEC FILINGSource text: [ID:n0001193125-26-203913]Further company coverage: DMRA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nFWN41H0WO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633665929","title":"Damora Therapeutics Inc - Lori Firmani to Cease Serving as CFO Effective May 1, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2633665929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633665929?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:21","pubTimestamp":1777926071,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nFWN41H0WO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633963927","title":"Damora Therapeutics names Brian Burkavage principal financial officer, accounting officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2633963927","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633963927?lang=en_us&edition=fundamental","pubTime":"2026-05-05 04:01","pubTimestamp":1777924862,"startTime":"0","endTime":"0","summary":"Damora Therapeutics set May 1, 2026 as effective date for CFO Lori Firmani to step down.Senior Vice President, Finance Brian Burkavage will become principal financial officer and principal accounting officer at that time.Burkavage previously served as senior vice president, finance and chief accounting officer at IO Biotech from November 2021 to December 2025.Earlier roles included controller at Passage Bio, director of financial planning and analysis at Aclaris Therapeutics, and 11 years at Ernst & Young in audit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLbYN4kT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRS","PASG","DMRA","BK4007","BK4139","IOBTQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632614801","title":"Damora Therapeutics grants options for 57,500 shares at $25.66 under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2632614801","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632614801?lang=en_us&edition=fundamental","pubTime":"2026-05-01 20:03","pubTimestamp":1777637005,"startTime":"0","endTime":"0","summary":"Damora Therapeutics granted non-qualified stock options covering 57,500 shares to two newly hired, non-executive employees.Options carry a 10-year term with an exercise price of $25.66 per share.Vesting schedules 25% on first anniversary of grant date.Remaining options vest in equal monthly installments over following 36 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief on May 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL1wBsjv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DMRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":65,"code":"91000000","status":"200"}]}}